Cascio C S, Kellar K J
Eur J Pharmacol. 1986 Jan 14;120(1):101-5. doi: 10.1016/0014-2999(86)90646-1.
[3H]Tryptamine binding sites were measured in 4 areas of rat brain following treatment with either pargyline or reserpine for 12 days, or 5 days and 30 days following intraventricular injections of 6-hydroxydopamine or 5,7-dihydroxytryptamine. Pargyline treatment decreased [3H]tryptamine binding in cerebral cortex, hippocampus, striatum and hypothalamus. Reserpine treatment increased binding in the cerebral cortex and hippocampus, but not in the striatum or hypothalamus. Neither 6-hydroxydopamine nor 5,7-dihydroxytryptamine altered [3H]tryptamine binding in any of the 4 brain areas. These results indicate that [3H]tryptamine binding sites in brain may be modified by drugs that can potentially affect tryptamine metabolism, and that the sites are not located on catecholamine or serotonin axons.
在用优降宁或利血平处理大鼠12天之后,或者在脑室内注射6-羟基多巴胺或5,7-二羟基色胺5天及30天之后,测定大鼠脑4个区域中的[3H]色胺结合位点。优降宁处理降低了大脑皮质、海马体、纹状体和下丘脑的[3H]色胺结合。利血平处理增加了大脑皮质和海马体中的结合,但纹状体和下丘脑未增加。6-羟基多巴胺和5,7-二羟基色胺均未改变4个脑区中任何一个区域的[3H]色胺结合。这些结果表明,脑中的[3H]色胺结合位点可能会被潜在影响色胺代谢的药物所改变,并且这些位点并不位于儿茶酚胺或5-羟色胺轴突上。